Edition:
United States

Inflarx NV (IFRX.OQ)

IFRX.OQ on NASDAQ Stock Exchange Global Select Market

34.45USD
2:06pm EDT
Change (% chg)

$0.16 (+0.47%)
Prev Close
$34.29
Open
$34.16
Day's High
$34.64
Day's Low
$34.05
Volume
779
Avg. Vol
14,953
52-wk High
$42.79
52-wk Low
$14.50

Latest Key Developments (Source: Significant Developments)

Inflarx N.V. Reports Q1 Loss Per Share Eur 0.40
Thursday, 17 May 2018 07:30am EDT 

May 17 (Reuters) - Inflarx NV ::INFLARX N.V. REPORTS FIRST QUARTER 2018 FINANCIAL & OPERATING RESULTS.Q1 LOSS PER SHARE EUR 0.40.CASH POSITION APPROXIMATELY US$137 MILLION (EUR 115 MILLION) AS OF MARCH 31, 2018.  Full Article

Inflarx Receives IND Acceptance To Proceed With A Phase IIB Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa
Tuesday, 9 Jan 2018 08:56am EST 

Jan 9 (Reuters) - Inflarx Nv ::INFLARX RECEIVES IND ACCEPTANCE TO PROCEED WITH A PHASE IIB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA.INFLARX NV - ‍INTENDS TO INITIATE THE STUDY ON IFX-1 IN Q1 OF 2018​.  Full Article

Ra Capital Management Reports 12.3 Pct Passive Stake In Inflarx Nv
Monday, 11 Dec 2017 05:33pm EST 

Dec 11 (Reuters) - Inflarx Nv ::RA CAPITAL MANAGEMENT LLC REPORTS 12.3 PERCENT PASSIVE STAKE IN INFLARX NV AS OF NOVEMBER 8 - SEC FILING.  Full Article

BRIEF-Inflarx Announces First Patient Enrolled In Phase Iib Trial With Lead Candidate Ifx-1 In Hidradenitis Suppurativa

* INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IIB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA Source text for Eikon: Further company coverage: